This activity was supported by Contract No. 200-2011-38807 (Task Order No. 75D30119F00080) and Contract No. HHSN263201800029I (Task Order No. HHSN26300008) with the Centers for Disease Control and ...

Bionano Symposium 2026 continues with Day 2: New Frontiers in Oncology and Bioprocessing Applications on February 24, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and ...

Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells more effectively. Their strategy targets a hidden “off switch” that tumors ...

Bionano Symposium 2026 continues with Day 3: OGM Making its Mark in Constitutional Genetic Disorders on February 25, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters ...

When 28-year-old mother Rachita Ramesh felt constant fatigue after childbirth, she blamed postpartum exhaustion, until unusual bleeding revealed Acute Lymphoblastic Leukaemia, leading to chemotherapy ...

The actor James Van Der Beek, who died on Wednesday at 48, was among a growing number of adults under 50 diagnosed with the disease. By Nina Agrawal The actor James Van Der Beek died on Wednesday at ...

On the occasion of Science Day, let us try to recall a few women scientists whose contributions led to development in various ...

(CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 ...

A breakthrough AI system is revolutionizing cancer immunotherapy by enabling scientists to design protein-based keys that train a patient s immune cells to attack cancer with extreme precision. This ...

Enhancer hijacking emerges as a major “missing driver” mechanism in LBCL/PCN, enabling detection of non-chimeric oncogene activation such as IGL::BCL2, IGH::CCND2, and MAFA/MAFB rearrangements.